PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
121.05%
EBIT growth of 121.05% while AXSM is zero. Bruce Berkowitz would see if small gains can be scaled further.
-6.92%
Negative operating income growth while AXSM is at 0.00%. Joel Greenblatt would press for urgent turnaround measures.
121.05%
Net income growth of 121.05% while AXSM is zero. Bruce Berkowitz would see if small gains can accelerate into a larger gap.
121.15%
EPS growth of 121.15% while AXSM is zero. Bruce Berkowitz would see if minimal gains can accelerate over time.
115.11%
Diluted EPS growth of 115.11% while AXSM is zero. Bruce Berkowitz would see if minimal gains can be scaled further for a bigger lead.
2.25%
Share change of 2.25% while AXSM is at zero. Bruce Berkowitz would see if slight buybacks (or dilution) matter in the bigger picture.
42.15%
Diluted share change of 42.15% while AXSM is zero. Bruce Berkowitz might see a minor difference that could widen over time.
No Data
No Data available this quarter, please select a different quarter.
-3.22%
Negative OCF growth while AXSM is at 0.00%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-8.23%
Negative FCF growth while AXSM is at 0.00%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-39049.73%
Negative 10Y OCF/share CAGR while AXSM stands at 0.00%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-717224.10%
Negative 5Y OCF/share CAGR while AXSM is at 0.00%. Joel Greenblatt would question the firm’s operational model or cost structure.
-12351.82%
Negative 3Y OCF/share CAGR while AXSM stands at 0.00%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
45138.86%
10Y net income/share CAGR of 45138.86% while AXSM is zero. Bruce Berkowitz would see if minor gains can compound into a bigger lead over time.
41496.01%
Net income/share CAGR of 41496.01% while AXSM is zero. Bruce Berkowitz would see if small mid-term gains can develop into a bigger lead.
7331.25%
3Y net income/share CAGR of 7331.25% while AXSM is zero. Bruce Berkowitz sees if minor improvements can widen to a bigger advantage.
8529.17%
Equity/share CAGR of 8529.17% while AXSM is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
2357.47%
Equity/share CAGR of 2357.47% while AXSM is zero. Bruce Berkowitz might see a minor advantage that could compound if the firm maintains positive net worth growth.
2495.43%
Equity/share CAGR of 2495.43% while AXSM is zero. Bruce Berkowitz sees if minor gains can snowball into a bigger lead soon.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
135.47%
Asset growth of 135.47% while AXSM is zero. Bruce Berkowitz checks if modest expansions can create a longer-term lead.
131.44%
BV/share growth of 131.44% while AXSM is zero. Bruce Berkowitz sees if small growth can compound into a strong advantage.
-41.82%
We’re deleveraging while AXSM stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-18.65%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
44.07%
SG&A growth of 44.07% while AXSM is zero. Bruce Berkowitz sees more spend on admin or marketing, expecting stronger top-line in return.